SG184089A1 - APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS - Google Patents

APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS Download PDF

Info

Publication number
SG184089A1
SG184089A1 SG2012068565A SG2012068565A SG184089A1 SG 184089 A1 SG184089 A1 SG 184089A1 SG 2012068565 A SG2012068565 A SG 2012068565A SG 2012068565 A SG2012068565 A SG 2012068565A SG 184089 A1 SG184089 A1 SG 184089A1
Authority
SG
Singapore
Prior art keywords
aptamer
ngf
disease
seq
deoxyuridine
Prior art date
Application number
SG2012068565A
Other languages
English (en)
Inventor
Daniel J Schneider
Akihiko Hisaminato
Sheela Waugh
Daniel Resnicow
Akira Nagabukuro
Toshihide Ono
Original Assignee
Somalogic Inc
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc, Otsuka Pharma Co Ltd filed Critical Somalogic Inc
Publication of SG184089A1 publication Critical patent/SG184089A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG2012068565A 2010-04-12 2011-04-12 APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS SG184089A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32314510P 2010-04-12 2010-04-12
PCT/US2011/032017 WO2011130195A1 (en) 2010-04-12 2011-04-12 APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS

Publications (1)

Publication Number Publication Date
SG184089A1 true SG184089A1 (en) 2012-11-29

Family

ID=44798979

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2014006522A SG2014006522A (en) 2010-04-12 2011-04-12 5-position modified pyrimidines and their use
SG2012068565A SG184089A1 (en) 2010-04-12 2011-04-12 APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS
SG2012074647A SG184497A1 (en) 2010-04-12 2011-04-12 5-position modified pyrimidines and their use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2014006522A SG2014006522A (en) 2010-04-12 2011-04-12 5-position modified pyrimidines and their use

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012074647A SG184497A1 (en) 2010-04-12 2011-04-12 5-position modified pyrimidines and their use

Country Status (24)

Country Link
US (7) US8598140B2 (enExample)
EP (3) EP2558586B1 (enExample)
JP (4) JP6012591B2 (enExample)
KR (4) KR102185779B1 (enExample)
CN (4) CN104069512A (enExample)
AR (1) AR081452A1 (enExample)
AU (2) AU2011240677B2 (enExample)
BR (2) BR122021003805B8 (enExample)
CA (3) CA2793451A1 (enExample)
CO (1) CO6630139A2 (enExample)
DK (1) DK2558478T3 (enExample)
EA (1) EA022429B1 (enExample)
ES (3) ES2905656T3 (enExample)
HK (1) HK1201740A1 (enExample)
IL (5) IL222339A (enExample)
MX (4) MX373860B (enExample)
MY (1) MY160608A (enExample)
NO (1) NO2558478T3 (enExample)
NZ (1) NZ602618A (enExample)
PH (1) PH12012501838A1 (enExample)
SG (3) SG2014006522A (enExample)
TW (6) TWI505833B (enExample)
UA (1) UA105290C2 (enExample)
WO (2) WO2011130289A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5993279A (ja) * 1982-11-17 1984-05-29 富士通株式会社 ロボツトによるカ−ド，レシ−ト分離取出し方法
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US8404830B2 (en) * 2007-07-17 2013-03-26 Somalogic, Inc. Method for generating aptamers with improved off-rates
EP2558586B1 (en) 2010-04-12 2016-10-12 Somalogic, Inc. APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS
AU2011323085B2 (en) 2010-11-05 2014-10-30 Miragen Therapeutics Base modified oligonucleotides
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
WO2013149086A1 (en) * 2012-03-28 2013-10-03 Somalogic, Inc. Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
HK1205764A1 (en) 2012-04-13 2015-12-24 Somalogic, Inc. Tuberculosis biomarkers and uses thereof
WO2014007438A1 (ko) 2012-07-02 2014-01-09 국립대학법인 울산과학기술대학교 산학협력단 페리오스틴에 대한 압타머 및 이를 포함하는 항암제 조성물
EP2912182B1 (en) 2012-10-23 2021-12-08 Caris Science, Inc. Aptamers and uses thereof
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
WO2014100434A1 (en) 2012-12-19 2014-06-26 Caris Science, Inc. Compositions and methods for aptamer screening
WO2014159669A2 (en) * 2013-03-14 2014-10-02 Somalogic, Inc. Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
TWI594975B (zh) 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
WO2014177510A2 (en) * 2013-05-03 2014-11-06 Creabilis Sa Polymer conjugates of indolocarbazole compounds in the treatment of pruritus
GB201312295D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Suppression of itch
CA3221709A1 (en) 2013-09-09 2015-03-12 Somalogic Operating Co., Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
CA2924987C (en) * 2013-09-24 2022-08-16 Somalogic, Inc. Multiaptamer target detection
JP2015062364A (ja) * 2013-09-25 2015-04-09 Ｎｅｃソリューションイノベータ株式会社 クレンブテロールに結合する核酸分子およびその用途
JP2015062365A (ja) * 2013-09-25 2015-04-09 Ｎｅｃソリューションイノベータ株式会社 ラクトパミンに結合する核酸分子およびその用途
WO2015066001A1 (en) * 2013-10-29 2015-05-07 Albert Einstein College Of Medicine Of Yeshiva University Nucleic acid-scaffolded small molecule libraries
BR112016010165A2 (pt) * 2013-11-21 2017-12-05 Somalogic Inc composições de nucleotídeos modificados de citidina-5-carboxamida e métodos relacionados às mesmas
HUE048529T2 (hu) * 2014-03-24 2020-07-28 Ribomic Inc FGF2-hez kötõdõ aptamer és alkalmazása
NO2718257T3 (enExample) 2014-05-30 2018-04-14
KR102541110B1 (ko) 2014-08-25 2023-06-08 에이뮨 테라퓨틱스, 인코퍼레이티드 난 단백질 제형 및 이의 제조 방법
CN104561013A (zh) * 2015-01-05 2015-04-29 中国人民解放军南京军区福州总医院 基于高通量测序技术进行核酸适配体序列优化的方法
CA3013917A1 (en) 2016-02-09 2017-08-17 Pharmakea, Inc. Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
SG11201807079UA (en) * 2016-03-14 2018-09-27 Somalogic Inc Compounds and methods for the synthesis of 5-(n-protected-tryptaminocarboxyamide)-2'-deoxyuridine phosphoramidate for incorporation into a nucleic sequence
CN107663220B (zh) * 2016-07-27 2020-10-02 上海伯豪医学检验所有限公司 修饰碱基、包含修饰碱基的核酸、适配体及其应用
JP2019535249A (ja) 2016-10-24 2019-12-12 バイオイズ カンパニー リミテッド ＴＮＦ−α結合アプタマー及びその治療的用途
EP3548652B1 (en) 2016-12-01 2024-04-03 Nautilus Subsidiary, Inc. Methods of assaying proteins
CA3086915A1 (en) 2017-12-29 2019-07-04 Sujal M. Patel Decoding approaches for protein identification
CN108299518A (zh) * 2018-02-02 2018-07-20 王成宇 一种2`-脱氧-β-尿苷的合成方法
JP7120531B2 (ja) 2018-02-12 2022-08-17 アプタキュア セラピューティクス リミテッド スクレロスチンに対するアプタマー及びその使用
CA3104041A1 (en) * 2018-06-22 2019-12-26 Somalogic, Inc. Improved proteomic multiplex assays
KR20210142694A (ko) 2019-03-22 2021-11-25 소마로직, 인크. 생물학적 복합 매트릭스에서 샘플-간 피분석물 변동성 감소
JP7748877B2 (ja) 2019-05-17 2025-10-03 ソマロジック オペレーティング カンパニー インコーポレイテッド 複雑な生物学的マトリックスにおける試料間分析物変動性の制御
CA3182266A1 (en) 2020-06-11 2021-12-16 Vadim Lobanov Methods and systems for computational decoding of biological, chemical, and physical entities
US12092642B2 (en) 2021-01-20 2024-09-17 Nautilus Subsidiary, Inc. Systems and methods for biomolecule quantitation
AU2022209365A1 (en) 2021-01-21 2023-07-20 Nautilus Subsidiary, Inc. Systems and methods for biomolecule preparation
IL305336B2 (en) 2021-03-11 2025-09-01 Nautilus Subsidiary Inc Systems and methods for preserving biomolecules
EP4316495A1 (en) 2021-03-25 2024-02-07 Aptacure Therapeutics Limited Nucleic acid molecule conjugate having prolonged in vivo half-life
CN113481204B (zh) * 2021-07-02 2022-08-12 湖南赛奥维生物技术有限公司 一种蛋白的核酸适配体、其衍生物及其应用
CA3227872A1 (en) 2021-09-09 2023-03-16 James Henry JOLY Characterization and localization of protein modifications
EP4405683A1 (en) 2021-09-22 2024-07-31 Nautilus Subsidiary, Inc. Methods and systems for determining polypeptide interactions
CN117916377A (zh) 2021-09-26 2024-04-19 安沛治疗有限公司 针对dkk1的适体及其用途
WO2023081728A1 (en) 2021-11-03 2023-05-11 Nautilus Biotechnology, Inc. Systems and methods for surface structuring
AU2023241893A1 (en) 2022-03-29 2024-09-26 Nautilus Subsidiary, Inc. Integrated arrays for single-analyte processes
WO2023212490A1 (en) 2022-04-25 2023-11-02 Nautilus Subsidiary, Inc. Systems and methods for assessing and improving the quality of multiplex molecular assays
US20250376716A1 (en) 2022-06-21 2025-12-11 Nautilus Subsidiary, Inc. Method for detecting analytes at sites of optically non-resolvable distances
WO2024059655A1 (en) 2022-09-15 2024-03-21 Nautilus Subsidiary, Inc. Characterizing accessibility of macromolecule structures
WO2024073599A1 (en) 2022-09-29 2024-04-04 Nautilus Subsidiary, Inc. Preparation of array surfaces for single-analyte processes
US20240183858A1 (en) 2022-11-15 2024-06-06 Nautilus Subsidiary, Inc. Standard polypeptides
WO2024124073A1 (en) 2022-12-09 2024-06-13 Nautilus Subsidiary, Inc. A method comprising performing on a single-analyte array at least 50 cycles of a process
US20240201182A1 (en) 2022-12-15 2024-06-20 Nautilus Subsidiary, Inc. Inhibition of photon phenomena on single molecule arrays
US20240241110A1 (en) 2023-01-12 2024-07-18 Nautilus Subsidiary, Inc. Characterization of glycans and glycoconjugates
WO2024206122A1 (en) 2023-03-24 2024-10-03 Nautilus Subsidiary, Inc. Improved transfer of nanoparticles to array surfaces
US20240353416A1 (en) 2023-04-13 2024-10-24 Nautilus Subsidiary, Inc. Artificial proteins for displaying epitopes
WO2024228396A1 (ja) * 2023-05-01 2024-11-07 株式会社ナティアス オリゴヌクレオチド合成用の高脂溶性ヌクレオチドビルディングブロックおよびこれを用いたオリゴヌクレオチドの合成
WO2024243237A1 (en) 2023-05-24 2024-11-28 Nautilus Subsidiary, Inc. Systems and methods for machine vision
US20250189519A1 (en) 2023-12-11 2025-06-12 Nautilus Subsidiary, Inc. Methods and compositions of particle-based arrays
WO2025137166A1 (en) 2023-12-20 2025-06-26 Nautilus Subsidiary, Inc. Fluidic devices for single-analyte assays
WO2025199236A1 (en) 2024-03-22 2025-09-25 Nautilus Subsidiary, Inc. Plasmonic particle systems for single-analyte assays
WO2025212338A1 (en) 2024-04-01 2025-10-09 Nautilus Subsidiary, Inc. Nanostructures for modulation of analyte conformation
CN119792485B (zh) * 2025-03-17 2025-06-24 温州医科大学附属口腔医院 一种抑菌促修复水凝胶敷料及制备方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267171A (en) 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4594339A (en) 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US5599720A (en) 1982-08-27 1997-02-04 Multilyte Limited Measurement of analyte concentration
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
DE3329892A1 (de) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4737453A (en) 1984-12-12 1988-04-12 Immunomedics, Inc. Sandwich immunoassay utilizing a separation specific binding substance
WO1986005803A1 (fr) 1985-03-30 1986-10-09 Marc Ballivet Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US4752566A (en) 1985-12-17 1988-06-21 Genetics Institute, Inc. Displacement polynucleotide method and reagent complex employing labeled probe polynucleotide
US5047519A (en) 1986-07-02 1991-09-10 E. I. Du Pont De Nemours And Company Alkynylamino-nucleotides
US4997818A (en) 1987-09-21 1991-03-05 The University Hospital Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas
SE8802173D0 (sv) 1988-06-10 1988-06-10 Astra Ab Pyrimidine derivatives
JPH05500799A (ja) * 1989-06-05 1993-02-18 ギリアド　サイエンシス，インコーポレイテッド エキソヌクレアーゼ抵抗性オリゴヌクレオチドおよびその調製方法
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
AU653504B2 (en) 1989-10-24 1994-10-06 Isis Pharmaceuticals, Inc. Oligonucleotide analogs with novel linkages
HUT61566A (en) 1990-03-13 1993-01-28 Acic Canada Inc Process for producing 2,2'-o-cyclonucleosides, nucleosides and their analogous compounds
WO1991014696A1 (en) 1990-03-29 1991-10-03 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US6030776A (en) 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US5476766A (en) 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
IL101038A0 (en) 1991-02-21 1992-11-15 Gilead Sciences Inc Agent specific for trombin and its use
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
US5840867A (en) * 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
CA2122365C (en) 1991-11-26 2010-05-11 Brian Froehler Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5580972A (en) 1993-06-14 1996-12-03 Nexstar Pharmaceuticals, Inc. Purine nucleoside modifications by palladium catalyzed methods
US5428149A (en) 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
US5719273A (en) 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
JP4899014B2 (ja) * 1995-06-02 2012-03-21 イーシー・テクノロジー・エルエルシー 求核試薬および一酸化炭素を用いるパラジウム触媒ヌクレオシド修飾方法
AU730154B2 (en) 1995-10-27 2001-03-01 Elliot R. Ramberg Methods and compositions for detection of specific nucleotide sequences
US5945527A (en) * 1996-05-30 1999-08-31 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6020483A (en) 1998-09-25 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleoside modifications by palladium catalyzed methods
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
JP3485023B2 (ja) * 1999-05-20 2004-01-13 東亞合成株式会社 ヌクレオシド化合物
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US7094770B2 (en) * 2000-04-13 2006-08-22 Pharmasset, Ltd. 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
AU2002360272A1 (en) 2001-10-10 2003-04-22 Superarray Bioscience Corporation Detecting targets by unique identifier nucleotide tags
EP1481090A4 (en) 2002-02-15 2006-08-09 Somalogic Inc METHOD AND REAGENTS FOR DETECTING BINDING OF TARGET MOLECULES BY NUCLEIC ACID ELECTRODES
EP1489171B1 (en) 2002-03-19 2012-10-31 Fujitsu Limited Functional molecule and process for producing the same
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
CA2407825A1 (en) 2002-10-11 2004-04-11 Andrew J. Simmonds Trap-tagging: a novel method for the identification and purification of rna-protein complexes
JP2006517790A (ja) 2003-01-09 2006-08-03 インヴィトロジェン コーポレーション ポリペプチド−核酸複合体の細胞の送達および活性化
JP4119976B2 (ja) * 2003-02-07 2008-07-16 国立大学法人群馬大学 ５位置換ピリミジンデオキシヌクレオチド誘導体、及びそれを用いた核酸の合成方法
US7329742B2 (en) 2003-09-04 2008-02-12 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
EP1584923A3 (en) 2004-04-07 2006-01-04 Roche Diagnostics GmbH Stabilization of biomolecules in samples
JP4584987B2 (ja) 2004-04-30 2010-11-24 アルニラム ファーマスーティカルズ インコーポレイテッド Ｃ５修飾ピリミジンを含むオリゴヌクレオチド
JP2006117542A (ja) * 2004-10-19 2006-05-11 Pias Arise Kk 神経成長因子産生抑制剤、並びにその神経成長因子産生抑制剤を配合した皮膚外用剤、化粧料、医薬部外品、痒み予防及び治療剤、及びアトピー性皮膚炎治療剤
WO2006063717A2 (en) 2004-12-16 2006-06-22 Febit Biotech Gmbh Polymerase-independent analysis of the sequence of polynucleotides
US7927798B2 (en) 2005-10-05 2011-04-19 Panomics, Inc. Detection of nucleic acids from whole blood
JP5256578B2 (ja) * 2005-12-20 2013-08-07 大正製薬株式会社 掻痒性皮膚疾患の予防または治療剤
SI1994171T1 (sl) 2006-01-17 2015-07-31 Somalogic, Inc. Multipleksirane analize testnih vzorcev
WO2007106503A2 (en) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
EP1897886A1 (en) 2006-09-08 2008-03-12 Bayer Schering Pharma Aktiengesellschaft Compounds as aptamer-dimers and their uses in diagnosis and therapy
US8242258B2 (en) * 2006-12-03 2012-08-14 Agilent Technologies, Inc. Protecting groups for RNA synthesis
EP2207891B1 (en) 2006-12-22 2012-07-25 Archemix LLC Materials and methods for the generation of transcripts comprising modified nucleotides
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
WO2008104408A2 (en) * 2007-02-27 2008-09-04 K. U. Leuven Research & Development Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
US20090137506A1 (en) * 2007-05-02 2009-05-28 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US8404830B2 (en) 2007-07-17 2013-03-26 Somalogic, Inc. Method for generating aptamers with improved off-rates
SI2489743T1 (sl) * 2007-07-17 2015-04-30 Somalogic, Inc. Aptameri s 5-(N-naftilno) substituiranimi uridini
US20090215050A1 (en) 2008-02-22 2009-08-27 Robert Delmar Jenison Systems and methods for point-of-care amplification and detection of polynucleotides
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
ES2543222T3 (es) * 2008-09-24 2015-08-17 Ribomic Inc. Aptámero para NGF y uso del mismo
EP2542266A4 (en) 2010-03-03 2013-10-23 Somalogic Inc 4-1BB-BINDING APTAMERS AND USE THEREOF IN THE TREATMENT OF DISEASES AND DISORDERS
BR112012024232A8 (pt) 2010-03-24 2018-02-06 Fujimoto Seiyaku Kk "aptâmero de 73 nucleotídeos ou menos, complexo, composição farmacêutica e medicamento anti-dor"
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
EP2558586B1 (en) * 2010-04-12 2016-10-12 Somalogic, Inc. APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS
WO2011130065A1 (en) 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2011323085B2 (en) * 2010-11-05 2014-10-30 Miragen Therapeutics Base modified oligonucleotides
WO2013149086A1 (en) * 2012-03-28 2013-10-03 Somalogic, Inc. Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
BR112016010165A2 (pt) 2013-11-21 2017-12-05 Somalogic Inc composições de nucleotídeos modificados de citidina-5-carboxamida e métodos relacionados às mesmas

Also Published As

Publication number Publication date
BR112012025872A2 (pt) 2016-10-18
CO6630139A2 (es) 2013-03-01
IL242038A0 (en) 2015-11-30
TW201629079A (zh) 2016-08-16
AR081452A1 (es) 2012-09-05
KR102185779B1 (ko) 2020-12-03
TW201900668A (zh) 2019-01-01
KR20180030229A (ko) 2018-03-21
KR101952671B1 (ko) 2019-02-27
CN102985435A (zh) 2013-03-20
TWI505833B (zh) 2015-11-01
IL256013A (en) 2018-01-31
IL256013B (en) 2018-05-31
AU2011240774A1 (en) 2012-10-18
AU2011240774B2 (en) 2014-04-10
ES2905656T3 (es) 2022-04-11
JP6352324B2 (ja) 2018-07-04
CN102858990B (zh) 2016-08-03
CN102858990A (zh) 2013-01-02
US9163056B2 (en) 2015-10-20
US20190233461A1 (en) 2019-08-01
MX392756B (es) 2025-03-24
TW202019943A (zh) 2020-06-01
TWI643864B (zh) 2018-12-11
EA201291034A1 (ru) 2013-04-30
AU2011240677A1 (en) 2012-11-01
CA3066785A1 (en) 2011-10-20
IL222339A (en) 2015-11-30
EP2558586A1 (en) 2013-02-20
ES2610159T3 (es) 2017-04-26
EP3345915A1 (en) 2018-07-11
KR20130043099A (ko) 2013-04-29
MX2012011771A (es) 2012-12-17
EP2558478A1 (en) 2013-02-20
CN107033204A (zh) 2017-08-11
JP2016145230A (ja) 2016-08-12
ES2667491T3 (es) 2018-05-11
US20140058076A1 (en) 2014-02-27
CA2797188A1 (en) 2011-10-20
IL252703A (en) 2017-12-31
KR101842269B1 (ko) 2018-03-26
DK2558478T3 (en) 2018-05-22
EA022429B1 (ru) 2015-12-30
US20180127450A1 (en) 2018-05-10
TWI593701B (zh) 2017-08-01
CA2793451A1 (en) 2011-10-20
SG2014006522A (en) 2014-03-28
BR122021003805B1 (pt) 2021-10-13
TW201936623A (zh) 2019-09-16
US20150376223A1 (en) 2015-12-31
WO2011130289A1 (en) 2011-10-20
US20160355540A1 (en) 2016-12-08
MX2020003168A (es) 2022-05-31
IL242038A (en) 2017-07-31
WO2011130195A1 (en) 2011-10-20
JP2013523177A (ja) 2013-06-17
IL256014A (en) 2018-01-31
HK1252803A1 (en) 2019-06-06
EP2558586B1 (en) 2016-10-12
BR122021003805B8 (pt) 2022-10-25
US8598140B2 (en) 2013-12-03
NZ602618A (en) 2013-12-20
CN104069512A (zh) 2014-10-01
TWI671309B (zh) 2019-09-11
UA105290C2 (ru) 2014-04-25
TWI684596B (zh) 2020-02-11
EP2558478B1 (en) 2018-03-07
NO2558478T3 (enExample) 2018-08-04
PH12012501838A1 (en) 2013-02-04
TW201134482A (en) 2011-10-16
CN102985435B (zh) 2016-10-26
JP7025818B2 (ja) 2022-02-25
KR20190018750A (ko) 2019-02-25
IL252703A0 (en) 2017-08-31
US20110275794A1 (en) 2011-11-10
JP2013523887A (ja) 2013-06-17
EP2558478A4 (en) 2013-10-23
US10221207B2 (en) 2019-03-05
MX373860B (es) 2020-03-25
US20130012693A1 (en) 2013-01-10
CA2797188C (en) 2020-03-31
EP2558586A4 (en) 2014-10-15
SG184497A1 (en) 2012-11-29
EP3345915B1 (en) 2021-11-24
AU2011240677B2 (en) 2015-05-14
TW201730198A (zh) 2017-09-01
MX2012011779A (es) 2012-12-17
BR112012025872B8 (pt) 2021-05-25
JP5901610B2 (ja) 2016-04-13
HK1201740A1 (en) 2015-09-11
JP6012591B2 (ja) 2016-10-26
IL222339A0 (en) 2012-12-31
IL256014B (en) 2018-05-31
MY160608A (en) 2017-03-15
JP2018109050A (ja) 2018-07-12
BR112012025872B1 (pt) 2021-04-20
KR20130103317A (ko) 2013-09-23

Similar Documents

Publication Publication Date Title
EP2558586B1 (en) APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS
AU2011223527B2 (en) Aptamers to 4-1BB and their use in treating diseases and disorders
CA2902186C (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
WO2013149086A1 (en) Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
EP3044334B1 (en) Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
HK1180368A (en) APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS
HK40033269A (en) Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
HK1217512B (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions